For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 1,916 | 1,212* | 1,814 | 1,279 |
| Research and development | 773 | 704* | 1,275 | 1,871 |
| Total operating expenses | 2,689 | 1,916 | 3,089 | 3,150 |
| Loss from operations | -2,689 | -1,916* | -3,089 | -3,150 |
| Gain on investment | - | 6* | - | - |
| Interest income | 1 | - | 5 | 1 |
| Interest expense | 100 | -80* | 111 | 72 |
| Interest expense - related party | - | 21* | - | - |
| Loss on extinguishment of debt | - | -206* | - | - |
| Loss on extinguishment of debt - related party | - | 83* | - | - |
| Interest expense - related party | 24 | - | - | - |
| Net change in fair value of derivative liability | -146 | -1,098* | 75 | - |
| Net change in fair value of trading marketable securities | - | 0* | 0 | 0 |
| Total other income (expense) | -269 | -1,322* | -31 | -71 |
| Provision for income taxes | - | 0* | 0 | 0 |
| Net loss | -2,958 | -3,238* | -3,120 | -3,221 |
| Foreign currency translation adjustments | 26 | -124 | 18 | -68 |
| Total other comprehensive income (loss) | 26 | -124* | 18 | - |
| Total comprehensive loss | -2,932 | -3,362 | -3,102 | -3,289 |
| Diluted EPS | -4 | -1.948 | -3.97 | -5.61 |
| Diluted Average Shares | 739,000 | 1,726,000 | 787,000 | 574,000 |
ARTELO BIOSCIENCES, INC. (ARTL)
ARTELO BIOSCIENCES, INC. (ARTL)